Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer

Bookmark and Share
Published: 2 Jun 2019
Views: 474
Dr Hedy Kindler - University of Chicago, Chicago, USA

Dr Hedy Kindler presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from the POLO trial.

This was a phase III randomised trial in which olaparib was administered to patients with BRCA-related pancreatic cancer who had not progressed after initial chemotherapy and compared with placebo.

After two years 22.1% of people receiving olaparib had no disease progression compared with 9.6% for those treated with placebo.

Watch the interview here.

Watch a comment from Dr. Suzanne Cole here.